As p-secretase, memapsin 2 cleaves amyloid-P precursor protein, which leads ultimately to the onset of Alzheimer's disease. As such, memapsin 2 is an excellent target of inhibitor drugs for the treatment of this disease. Here we describe the tools for memapsin 2 inhibitor design that have been developed and results from the structure-based inhibitor design. Strategy for the design of memapsin 2 inhibitors with pharmaceutical potential is also discussed.
Introduction
Accumulation of the amyloid-/l peptide (AB) in the brain is now believed to be the primary cause of the neurodegeneration and progression of Alzheimer's disease (AD) [l]. Ap is a fragment of amyloid-/3 precursor protein (APP), released by two proteases known as the p-and y-secretases.
Since there is no effective drug for treatment of AD at present, there is an intense interest in potential therapeutic targets. p-Secretase is a particularly exciting therapeutic target for several reasons. This protease initiates the first step in Ap production. Thus, inhibition of its activity would block the entire cascade of AD pathogenesis. Additionally, the fact that p-secretase is an aspartic protease has also raised the hope that its therapeutic inhibitor can be as successful as that against HIV protease. Finally, the absence of a functional p-secretase gene in mice did not produce a clear phenotype, suggesting that the inhibition of this protease in therapy is physiologically tolerable P-Secretase is a membrane-anchored aspartic protease [5-91. Since this historical name did not appropriately reflect its protease nature, several new names were given. The name memapsin 2 [9] is rooted in 'membrane aspartic grotease of the pepsin family' and the numeral 2 distinguishes it from a homologous protease, memapsin 1. This name conforms with the nomenclature of aspartic proteases recommended by the IUBMB's Enzyme Nomenclature ([lo] ; also at http:// www .chem. qmw .ac .uk/iubmb/enzyme/EC34/ 3423.html#23), e.g. pepsin, gastricsin, cathepsin, etc., and thus will be used here. Other names used were BACE [5], 8] and membranebound aspartic protease [7] Memapsin 2 activity and firstgeneration inhibitors
As has been observed with other mammalian aspartic proteases, memapsin 2 mRNA encodes for a pre-pro-memapsin 2. Uniquely present is the C-terminal extension of a transmembrane and intracellular region. Cellular processing by furin at an Arg45-G1~46 bond in the pro region produces G l~~~-m e m a p s i n 2 [ll-141. T h e optimal pH for memapsin 2 lies in the range 3.5-4. 
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Fiwm I X-ray crystal structure of the active site of memapsin 2 complexed with inhibitor OM99-2 Blue nitrogen and red oxygen atoms of inhibitor (brown), which hydrogen-bond to atoms of memapsin 2 residues (blue), are linked by broken lines. Positions of substrate are labelled Pn.
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1 r Crystal structure of memapsin 2 complexed to inhibitor OM99-2
In order to learn the interactions of the memapsin 2 active site with an inhibitor, we solved the X-ray crystallographic structure of recombinant memapsin 2 protease domain bound to inhibitor OM99-2 [18] . T h e overall folding of the memapsin 2 catalytic domain is homologous to other mammalian aspartic proteases [18] . Most of the C-terminal extension unique for memapsins is part of the folding of the globular catalytic unit. T h e inhibitor is bound in the substrate-binding cleft located between the N-and C-terminal lobes.
Six of the eight OM99-2 residues (P,-P;) are bound in the active site of memapsin 2 in an extended structure and their respective binding sites (S,-S;) are well defined from atomic contacts with the inhibitor side chains (Figure 1 ). The P L and Pi side chains have less interaction with the enzyme and are mobile in the crystal structure. There is extensive hydrogen bonding between memapsin 2 to the polypeptide backbone of OM99-2 and some of the more polar inhibitor side chains, such as P,-Glu and P,-Asn. On the other hand, the contacts between the protease subsites to side chains at P,-Val, PI-Leu, Pi-Ala and Pi-Ala are mostly hydrophobic and van-der-Waal interactions. This
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structural model is important for the design of a new generation of memapsin 2 inhibitors.
Structure-based design of secondgeneration inhibitors
T h e crystal structure of memapsin 2-OM99-2 was used to design smaller yet still potent inhibitors. In the X-ray crystal structure, the inhibitor chain turns at the Pi position and the P;-P; side-chain residues are not involved in any specific interaction in this region. In the design of new inhibitors [19], we substituted the P;-P; residues with a simple benzylamine group and installed different sidechain structures at P,, P,, Pi and Pi. The P, residue was also simplified or eliminated. T h e most potent resulting inhibitor, GT-1017 (Figure 2) , was 722 Da with a Ki of 2.5 nM [19] . Compared with OM99-2, which is 1100 Da with a Ki Inhibitor GT-I0 I 7 of 1.7 nM, the structure-based design reduced the inhibitor size considerably yet retained the potency. These results show excellent promise for the structure-based design of memapsin 2 inhibitors in the future.
Complete subsite specificity of memapsin 2
Although OM99-2 had excellent inhibition potency, it was designed based on limited information about memapsin 2 specificity. Like other mammalian aspartic proteases, the active site of memapsin 2 can accommodate eight subsites, six of which (P,-P;) have clear interaction with the enzyme [18] . We have since determined the complete residue preferences in all eight memapsin 2 subsites [20] (Figure 3) . A compiled sequence for the most preferred residue in each subsite is EIDL/MVLD (where / denotes a scissile bond).
Second-and third-ranking preferred residues in each subsite are QVNF/EIWE and D L M M / QAVW, respectively. It is clear that memapsin 2 has non-stringent specificity in all eight subsites. This is particularly true for subsites Pj and Pi, in agreement with the lack of side-chain interaction of these two inhibitor residues in the crystal structure. It is also interesting to note that in the sequence around the p-secretase site of Swedish APP, residues in P,-PI (EVNL) are among the most or second-most preferred, while residues in P;-P; (DAEF) are among the most favoured. T h e most dramatic gain in the hydrolytic efficiency due to APP Swedish mutation appears to be the Lys-to-Asn substitution at P,. Since the PI Metto-Leu substitution has a lesser effect, this raises an interesting question of whether an APP P, mutation alone to residues such as Asn or Asp is sufficient to bring about an early onset of AD. 
I I W F Y M L I V A G T S Q N E D H R K P W F Y M L I V A G T S Q N E D H R K P W F Y M L I V A G T S Q N E D H R K P W F Y M L I V A G T S Q N E D H R K P W F Y M L I V A G T S Q N E D H R K P W F Y M L I V A G T S Q N E D H R K P W F Y M L I V A G T S Q N E D H R K P

Amyloidogenic Proteins Involved in Neurodegeneration and Therapeutic Implications
Subsite residue preference has also been determined for memapsin 2 inhibitors using a combinatorial peptide-inhibitor library with residues randomized at four subsite positions [20] .
T h e consensus residues (P3, L or I ; P,, D ; Pi, V ; Pi, E) are in good agreement with substrate specificity information (Figure l) , except at the P;
position.
Strategy in the design of newgeneration in hi bitors
T h e design of memapsin 2 inhibitor drugs is more challenging than most because, in addition to the desired properties, such as high potency, high selectivity, low toxicity and good pharmacokinetic properties, they must also penetrate the bloodbrain barrier to reach the brain. with the protease not observed in the OM99-2-memapsin 2 structure [18] . This structure provides a new option in the design of memapsin 2 inhibitors in which Pi and Pi are included, while the residues at the N-terminal side of the inhibitors may be omitted to reduce the size. Our experience supports the view that the structure-based inhibitor-design cycle would be of great value in the evolution of clinically useful memapsin 2 inhibitors. One of the most challenging problems in the design of memapsin 2 inhibitors may be the inhibition selectivity against memapsin 1. T h e specificity of the two memapsins is very similar
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[20] and some of the potent memapsin 2 inhibitors inhibit memapsin 1 equally well [19] . A structure of memapsin 1's interaction with an inhibitor such as OM00-3 would be very helpful for future selectivity design.
